Australia's most trusted
source of pharma news
Thursday, 05 March 2026
Posted 5 March 2026 AM
A Menarini appears steadfast in its attempt to secure subsidy for Orserdu by resubmitting an application to MSAC, suggesting that the oral SERD could land on the PBAC’s July agenda.
While approved by the TGA, Orserdu is not currently listed on the ARTG as the company has decided not to supply the medicine in Australia for the time being, likely due to its high cost. It’s understood to cost more than US$250,000 for a full year of treatment in the US.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.